You are here

Positive Phase III Results for Extended-Release Topiramate in Epilepsy Patients

FDA review expected in December (May 22)

Positive results have been reported from a global phase III study of extended-release topiramate (USL255; Upsher-Smith Laboratories) in adults with epilepsy. A new drug application (NDA) for the compound has been accepted for review by the FDA, with an anticipated target review date of December 2013.

In the new study, USL255 demonstrated a positive treatment effect as adjunctive therapy in patients with refractory partial-onset seizures (POS) compared with placebo. The drug achieved a statistically significant reduction from baseline in the weekly frequency of POS during the titration-plus-maintenance phase compared with placebo (P

Preliminary findings from this study will be presented at the 2013 Annual Meeting of the American Epilepsy Society, to be held Dec. 6–10 in Washington, D.C.

The phase III PREVAIL trial was a randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of USL255 as adjunctive therapy in patients with refractory POS.

An open-label extension study to evaluate the safety of USL255 as adjunctive therapy in patients with refractory POS who had participated in PREVAIL is ongoing.

Source: Upsher-Smith Laboratories; May 22, 2013.

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
Mesh Implants, Now Banned by FDA, Work as Well as Hysterectomy
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug